Approximately 50% of the lung adenocarcinomas without non-invasive components were positive for GBP1, in contrast to previous findings that demonstrated that only 12.5% of the tumors were positive in patients with lung adenocarcinomas containing non-invasive components (5). This evidence concerns the gene GBP1 and lung adenocarcinoma.